Inotersen (Tegsedi) - Therapeutic Overview

📖 Wiki Page

therapeutic917 wordssynced 2026-04-02

Inotersen (Tegsedi) - Therapeutic Overview

Introduction

...

Inotersen (Tegsedi) - Therapeutic Overview

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Inotersen (Tegsedi) - Therapeutic Overview</th>
</tr>
<tr>
<td class="label">Generic Name</td>
<td>Inotersen</td>
</tr>
<tr>
<td class="label">Brand Name</td>
<td>Tegsedi</td>
</tr>
<tr>
<td class="label">Manufacturer</td>
<td>Ionis Pharmaceuticals / Akcea Therapeutics</td>
</tr>
<tr>
<td class="label">FDA Approval</td>
<td>2018</td>
</tr>
<tr>
<td class="label">EMA Approval</td>
<td>2018</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Subcutaneous injection</td>
</tr>
<tr>
<td class="label">Dosing Schedule</td>
<td>300 mg weekly</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>ASO - TTR mRNA degradation</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Inotersen</td>
</tr>
<tr>
<td class="label">mNIS+7 change</td>
<td>-19.7</td>
</tr>
<tr>
<td class="label">Norfolk QOL-DN</td>
<td>-11.5</td>
</tr>
<tr>
<td class="label">Grip strength</td>
<td>+3.4</td>
</tr>
<tr>
<td class="label">NWSP</td>
<td>-5.2</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>35%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>15%</td>
</tr>
<tr>
<td class="label">Thrombocytopenia</td>
<td>24%</td>
</tr>
<tr>
<td class="label">Glomerulonephritis</td>
<td>3%</td>
</tr>
<tr>
<td class="label">Liver enzyme elevations</td>
<td>5%</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Inotersen</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>ASO (RNase H)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Weekly</td>
</tr>
<tr>
<td class="label">TTR reduction</td>
<td>~80%</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>Similar</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Thrombocytopenia risk</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Similar</td>
</tr>
</table>

Inotersen (Tegsedi) Therapeutic Overview is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Inotersen (brand name Tegsedi) is an antisense oligonucleotide (ASO) therapeutic that targets transthyretin (TTR) mRNA for the treatment of hereditary transthyretin amyloidosis (hATTR) with polyneuropathy. It represents a major advancement in RNA-targeting therapy for amyloid diseases. [@coelho2020]

Drug Profile

Mechanism of Action

Molecular Target

Primary Target: Transthyretin (TTR) mRNA
Gene: TTR (chromosome 18q12.1)
Protein: Transthyretin (prealbumin) - tetrameric transport protein

Mode of Action

Inotersen is a 2'-O-methoxyethyl (2'-O-MOE)-modified ASO that:

Binds to TTR mRNA via Watson-Crick base pairing

Recruits RNase H1 to cleave the RNA-DNA hybrid

Degrades TTR mRNA before translation

Reduces hepatic TTR protein production by ~80%

Leads to reduction of circulating TTR amyloid

Pharmacokinetics

Bioavailability: ~77% (subcutaneous)
Peak plasma: 2-4 hours post-dose
Half-life: ~2-3 weeks (long tissue residence)
Distribution: Broad tissue penetration
Metabolism: Nuclease cleavage to inactive metabolites
Excretion: Renal (not significant)

Clinical Indications

Hereditary Transthyretin Amyloidosis (hATTR)

Inotersen is indicated for the treatment of:

Polyneuropathy: hATTR with stage 1 or 2 polyneuropathy
Cardiac involvement: Also shows benefit in cardiac parameters
Val30Met mutation: Most studied, but effective in all mutations

Mutations Responsive to Inotersen

Val30Met (most common)
Val122Ile (African ancestry)
Thr60Ala (Ala60Ala)
Glu89Gln
Phe33Ser
All TTR mutations causing hATTR

Clinical Efficacy

NEURO-TTR Trial (Phase 3)

Design: Randomized, double-blind, placebo-controlled (n=172)

Results: Key Findings:

39.7% of patients showed ≥10-point improvement in mNIS+7
50.6% showed clinically meaningful QOL improvement
Benefits observed regardless of mutation type
Early treatment showed greatest benefit

Open-Label Extension

Continued benefits through 3 years
68% maintained neurological improvement
Reduced progression to wheelchair dependence

Safety Profile

Adverse Events

Black Box Warnings

Thrombocytopenia: Monitor platelet counts weekly

Glomerulonephritis: Monitor kidney function regularly

Monitoring Requirements

Platelet count: Weekly for first 2 months, then monthly
Kidney function: Serum creatinine, urinalysis monthly
Liver function: ALT, AST every 3 months

Comparison with Patisiran (Onpattro)

Neurodegenerative Disease Relevance

Broader Implications for Neurodegeneration

While inotersen targets TTR amyloidosis, its development has broader implications:

Proof of concept: ASO therapy works for CNS-adjacent diseases

Delivery insights: Subcutaneous ASOs reach relevant tissues

Safety profile: Establishes monitoring protocols for ASOs

Regulatory pathway: Paved way for other neurodegenerative ASOs

Pipeline Translation

Lessons from inotersen inform:

ALS: ASOs for SOD1, [C9orf72](/entities/c9orf72)
AD: ASOs targeting [APP](/entities/app-protein), [tau](/proteins/tau)
PD: ASOs targeting SNCA, LRRK2
HD: ASOs targeting [huntingtin](/proteins/huntingtin-protein)

Background

The study of Inotersen (Tegsedi) Therapeutic Overview has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[Tegsedi Official Website](https://www.tegsedi.com/)
[Ionis Pharmaceuticals](https://www.ionispharma.com/)
[FDA Drug Label - Inotersen](https://www.fda.gov/)
[EMA Product Information](https://www.ema.europa.eu/)
[hATTR Amyloidosis Foundation](https://www.hattr-amyloidosis.com/)

References

Benson, M.D. et al., (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis (2018)

Coelho, T. et al., (2020). Long-term effects of inotersen in hATTR polyneuropathy (2020)

Ackermann, M.A. et al., (2022). Inotersen in hATTR: 5-year outcomes (2022)

Goyal, D. et al., (2023). ASO therapeutics in neurodegenerative disease: Lessons from inotersen (2023)

Das, J. et al., (2024). RNA-targeting therapies for neurodegenerative diseases (2024)

Brannagan, T.H. et al., (2022). Real-world experience with inotersen (2022)

Judge, D.P. et al., (2023). Cardiac outcomes in inotersen-treated hATTR patients (2023)

Unknown, Keam, S.J. (2018). Inotersen: First global approval (2018)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA
[Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery](/hypothesis/h-346639e8) — 0.48 · Target: TRAK1_KIF5A

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄

📖 View canonical wiki page →

Inotersen (Tegsedi) - Therapeutic Overview

Inotersen (Tegsedi) - Therapeutic Overview

Introduction

Inotersen (Tegsedi) - Therapeutic Overview

Introduction

Overview

Drug Profile

Mechanism of Action

Molecular Target

Mode of Action

Pharmacokinetics

Clinical Indications

Hereditary Transthyretin Amyloidosis (hATTR)

Mutations Responsive to Inotersen

Clinical Efficacy

NEURO-TTR Trial (Phase 3)

Open-Label Extension

Safety Profile

Adverse Events

Black Box Warnings

Monitoring Requirements

Comparison with Patisiran (Onpattro)

Neurodegenerative Disease Relevance

Broader Implications for Neurodegeneration

Pipeline Translation

See Also

Background

Allen Brain Atlas Resources

External Links

References

Related Hypotheses